A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma

Authors :: Diane D. Liu
Marta Penas-Prado
Stan Xiaosi Han
Barbara O’Brien
Shiao-Pei Weathers
Ivo W. Tremont-Lukats
Charles A. Conrad
Monica Loghin
W. K. Alfred Yung
John de Groot
Mark R. Gilbert
Vinay K. Puduvalli
Source :: Journal of Clinical Oncology. 33:2005-2005
Publication Year :: 2015
Publisher :: American Society of Clinical Oncology (ASCO), 2015.
Abstract: 2005 Background: Antiangiogenic therapy can rapidly reduce vascular permeability, but high doses of bevacizumab (BEV) may induce selective pressure to promote resistance. This trial evaluated the e...

Subjects :: Oncology
Cancer Research
medicine.medical_specialty
Bevacizumab
business.industry
Recurrent glioblastoma
Low dose
Antiangiogenic therapy
food and beverages
Vascular permeability
Lomustine
Internal medicine
medicine
High doses
Nuclear medicine
business
medicine.drug

Tools